EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dexmedetomidine alleviates cognitive impairment by promoting hippocampal neurogenesis via BDNF/TrkB/CREB signaling pathway in hypoxic–ischemic neonatal rats

Xiaohui Chen, Andi Chen, Jianjie Wei, Yongxin Huang, Jianhui Deng, Pinzhong Chen, Yanlin Yan, Mingxue Lin, Lifei Chen, Jiuyun Zhang, Zhibin Huang, Xiaoqian Zeng und 2 weitere

CNS Neuroscience & Therapeutics · 2024-01 · 30 (1)

DOI: 10.1111/cns.14486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 13.10.2023. Verfasst von Xiaohui Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Dexmedetomidine, Hypoxia-Ischemia, Brain, Cognitive Dysfunction. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Training Project for Talents of Fujian Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Dexmedetomidine (DEX) has been reported to alleviate hypoxic–ischemic brain damage (HIBD) in neonates. This study aimed to investigate whether DEX improves cognitive impairment by promoting hippocampal neurogenesis via the BDNF/TrkB/CREB signaling pathway in neonatal rats with HIBD.

Methods

HIBD was induced in postnatal day 7 rats using the Rice‐Vannucci method, and DEX (25 μg/kg) was administered intraperitoneally immediately after the HIBD induction. The BDNF/TrkB/CREB pathway was regulated by administering the TrkB receptor antagonist ANA‐12 through intraperitoneal injection or by delivering adeno‐associated virus (AAV)‐shRNA‐BDNF via intrahippocampal injection. Western blot was performed to measure the levels of BDNF, TrkB, and CREB. Immunofluorescence staining was utilized to identify the polarization of astrocytes and evaluate the levels of neurogenesis in the dentate gyrus of the hippocampus. Nissl and TTC staining were performed to evaluate the extent of neuronal damage. The MWM test was conducted to evaluate spatial learning and memory ability.

Results

The levels of BDNF and neurogenesis exhibited a notable decrease in the hippocampus of neonatal rats after HIBD, as determined by RNA‐sequencing technology. Our results demonstrated that treatment with DEX effectively increased the protein expression of BDNF and the phosphorylation of TrkB and CREB, promoting neurogenesis in the dentate gyrus of the hippocampus in neonatal rats with HIBD. Specifically, DEX treatment significantly augmented the expression of BDNF in hippocampal astrocytes, while decreasing the proportion of detrimental A1 astrocytes and increasing the proportion of beneficial A2 astrocytes in neonatal rats with HIBD. Furthermore, inhibiting the BDNF/TrkB/CREB pathway using either ANA‐12 or AAV‐shRNA‐BDNF significantly counteracted the advantageous outcomes of DEX on hippocampal neurogenesis, neuronal survival, and cognitive improvement.

Conclusions

DEX promoted neurogenesis in the hippocampus by activating the BDNF/TrkB/CREB pathway through the induction of polarization of A1 astrocytes toward A2 astrocytes, subsequently mitigating neuronal damage and cognitive impairment in neonates with HIBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineHypoxia-Ischemia, BrainCognitive DysfunctionRatsAnimalsAnimals, NewbornRats, Sprague-DawleyBrain-Derived Neurotrophic FactorHippocampusSignal TransductionRNA, Small InterferingNeurogenesis

Stichwörter der Autor:innen

BDNFastrocytecognitive impairmenthippocampal neurogenesishypoxic-ischemic brain damage

Substanzen

DexmedetomidineBrain-Derived Neurotrophic FactorRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
  • Fujian Provincial Key Laboratory of Emergency Medicine, Fuzhou, China.
  • Fujian Emergency Medical Center, Fujian Provincial Key Laboratory of Critical Care Medicine, Fujian Provincial Co-Constructed Laboratory of "Belt and Road", Fuzhou, China.

ORCID-Profile: Xiaochun Zheng

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Training Project for Talents of Fujian Provincial Health Commission

Zitieren

APA

Chen, X., Chen, A., Wei, J., Huang, Y., Deng, J., Chen, P., Yan, Y., Lin, M., Chen, L., Zhang, J., Huang, Z., Zeng, X., Gong, C., & Zheng, X. (2024). Dexmedetomidine alleviates cognitive impairment by promoting hippocampal neurogenesis via BDNF/TrkB/CREB signaling pathway in hypoxic–ischemic neonatal rats. CNS Neuroscience & Therapeutics, 30(1). https://doi.org/10.1111/cns.14486

Vancouver

Chen X, Chen A, Wei J, Huang Y, Deng J, Chen P, et al. Dexmedetomidine alleviates cognitive impairment by promoting hippocampal neurogenesis via BDNF/TrkB/CREB signaling pathway in hypoxic–ischemic neonatal rats. CNS Neuroscience & Therapeutics. 2024;30(1). doi:10.1111/cns.14486

BibTeX
@article{Chen2024,
  author = {Chen, Xiaohui and Chen, Andi and Wei, Jianjie and Huang, Yongxin and Deng, Jianhui and Chen, Pinzhong and Yan, Yanlin and Lin, Mingxue and Chen, Lifei and Zhang, Jiuyun and Huang, Zhibin and Zeng, Xiaoqian and Gong, Cansheng and Zheng, Xiaochun},
  title = {Dexmedetomidine alleviates cognitive impairment by promoting hippocampal neurogenesis via BDNF/TrkB/CREB signaling pathway in hypoxic–ischemic neonatal rats},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  volume = {30},
  number = {1},
  doi = {10.1111/cns.14486}
}
Kostenlos starten →